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Edited by Robert B. RussellAbstract The class IIIa adenylyl cyclase (AC) Rv1625c from
Mycobacterium tuberculosis forms homodimers with two cata-
lytic centres, whereas the Paramecium guanylyl and mammalian
ACs operate as pseudoheterodimers with one catalytic centre.
The functional and structural relationship of the catalytic
domains of these related class III cyclases was investigated.
Point mutations introduced into Rv1625c to engineer a forskolin-
binding pocket created a single heterodimeric catalytic centre,
yet did not result in forskolin activation. Chimerization of these
Rv1625c point mutants with corresponding mammalian AC
domains was impossible. However, it was successful using a
complemental Paramecium guanylyl cyclase domain and resulted
in an AC. The data signify a divergence of structural and
functional evolution in class III Acs.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In mammals the second messengers cAMP and cGMP are
synthesized by adenylyl cyclases (ACs) and guanylyl cyclases
(GCs), respectively. The catalytic domains are similar and are
often referred to as cyclase homology domains (CHDs). A re-
cent analysis has subclassiﬁed mammalian GCs and mem-
brane-bound ACs as class IIIa cyclases, together with
protozoan ACs and GCs as well as many eubacterial ACs [1].
The catalytic centre is formed at the interface from either dif-
ferent CHDs (C1 and C2, one catalytic centre) or identical
CHDs (two catalytic centres, Fig. 1(a)) [2,3]. The domain
compatibility of diﬀerent isoforms of class IIIa CHDs appears
to be high, because active heterodimers can be reconstituted in
vitro, e.g., mammalian ACs type V C1+ type II C2, type I
C1+ type II C2 and even mammalian type V AC C2+ soluble
GC-a1 [4–6]. This functional compatibility has been further
extended by the successful heterodimerization of mammalian
CHDs (type II C2, type IX C2) and a corresponding Parame-
cium GC C2 domain, demonstrating a structural as well as
functional conservation of catalytic centres from metazoan and* Corresponding author. Fax: +49-7071-295952.
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membrane-bound AC Rv1625c from Mycobacterium tubercu-
losis, which is topologically identical to one half of a
mammalian AC, was characterized [3,8,9]. Here, we ask whe-
ther the mycobacterial monomer can functionally interact with
eukaryotic CHDs. We demonstrate that an inactive point
mutant (D300A) of Rv1625c, which is equivalent to a mam-
malian C2-CHD, can be reconstituted with an inactive C2
domain (C1 equivalent) of the Paramecium GC (Fig. 1(a)). The
chimera exclusively uses ATP as a substrate. The results char-
acterize the structural and functional relationship of mamma-
lian, protozoan and bacterial class IIIa CHDs.2. Materials and methods
2.1. Plasmid construction
Cloning of Rv1625cD300A, the C2 domains of rat type II and
mouse type IX ACs, and the C2 domain of a GC from Paramecium
tetraurelia 51s was as reported earlier [3,7]. A pQE60-based expression
plasmid for the C1-CHD of type I AC was provided by Kleuss and
coworkers [10]. The type V AC C1 domain from rabbit (amino acids
405–645, GenBank Accession No. P40144) was ﬁtted with a 50-SalI
and a 30-MluI site and cloned into a modiﬁed pQE30-vector [7].
Thereby, an N-terminal MRGSH6GVD metal-aﬃnity tag and a C-
terminal TRLSLIS heptapeptide extension were added. The bovine
type VII AC C1 domain (amino acids 222–485, GenBank Accession
No. Q29450) was cloned identically.
Mutants Rv1625cD300S, Rv1625cN372A and Rv1625cN372T were
generated by PCR using the DNA of the catalytic domain of Rv1625c
as a template and cloned into pQE30 [3]. Expression and puriﬁcation
of recombinant proteins was as reported [3,7].
2.2. Cyclase assays
The reactions contained in 100 ll of 50 mM Tris–HCl, pH 7.5, 22%
glycerol, 2 mM MnCl2, 75 lM [a-32P]ATP (unless stated otherwise)
and 2 mM [2,8-3H]cAMP. Ingredients were mixed on ice 10 min prior
to the start of the reaction. AC activity was determined at 30 C for 10
min. Standard errors of the mean (S.E.M.) of multiple assays were
usually <10%. GC activity was determined identically using GTP as a
substrate [11,12].3. Results and discussion
3.1. The catalytic and forskolin-binding sites in class IIIa
adenylyl cyclases
In the catalytic domain of the mycobacterial AC, Rv1625c
functions are incorporated which in mammalian ACs are dis-
tributed between two similar, individually inactive CHDs, C1
and C2 [3]. Consequently, Rv1625c is active as a homodimer
with two functional catalytic centres, whereas mammalian ACsblished by Elsevier B.V. All rights reserved.
Fig. 1. Heterodimeric class IIIa AC catalysts. (a) Structural compari-
son of the homodimeric Rv1625c with two catalytic centres versus
heterodimeric catalysts harbouring a single catalytic centre. Purine
triphosphates are sketched by moieties. Pu: purine; Me: metal
ion-cofactor; P: phosphate moiety. C: homodimeric CHD; C1, C2:
heterodimeric CHDs. Examples are given in the respective boxes. (b)
Titration of 45 nM Rv1625cN372A with an excess of Rv1625cD300A
(squares). Circles: Rv1625cD300A alone. Inset: 15% PAGE of
puriﬁed recombinant proteins (2 lg per lane). (c) Titration of
45 nM Rv1625cN372T with Rv1625cD300S (squares). Circles:
Rv1625cD300S alone. Inset: 15% PAGE of puriﬁed recombinant
proteins (1 and 2 lg per lane, respectively). Both titrations were con-
ducted at 85 lM ATP.
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AC type IX, the second location evolved as a site which makes
the heterodimer susceptible to activation by the plant diterpene
forskolin [2]. Therefore, in a ﬁrst step to resolve the structural
relationship between mycobacterial and mammalian AC cat-
alysts, we created a mycobacterial heterodimeric AC by in-
troduction of point mutations which eﬀectively generated
mycobacterial C1 or C2 equivalents (Fig. 1(a), [3]). For ex-
ample, Rv1625cN372A and Rv1625cR376A or Rv1625-
cD256A and Rv1625cD300A correspond to mammalian C1
and C2 domains, respectively, are catalytically incompetent
alone and complement each other. Rv1625cN372A and
Rv1625cR376A lack transition-state stabilizing amino acids,
whereas Rv1625cD256A and Rv1625cD300A each miss a
metal-cofactor binding aspartate. For example, Rv1625-
cN372A, a C1 equivalent, complements Rv1625cD300A re-
sulting in wild-type AC activity of 2.5 lmol cAMPmg1 min1
(Fig. 1(b)). This proved that D300 in a C2-equivalent and
N372 in a C1 equivalent were dispensable for dimer formation.
Next, we attempted to create an environment for forskolin
binding. Eleven conserved amino acids were identiﬁed as for-
skolin contacts in the structures of mammalian ACs, i.e.,
Phe394, Tyr443, Val506, Tyr507, Ser508, Val511 and Thr512
in C1 (ACV numbering) and Leu912, Ile940, Gly941 and
Ser942 in C2 (ACII numbering) [2,13]. Six of these residues aresimilar or identical in Rv1625c (see [3] for alignment). Asp300
and Asn372 in Rv1625c are at the positions of Ser942 and
Thr512, respectively, and are predicted to impede forskolin
binding [2]. Accordingly, we generated the heterodimer
Rv1625cD300S/Rv1625cN372T. With now 8 out of 11 amino
acids known to contact forskolin either similar or identical, we
dismissed further mutations at this point to avoid unpredict-
able structural changes. In fact, we expected that with this
reconstructed binding pocket the diterpene might at least cause
a small and consistent activation. Rv1625cD300S and
Rv1625cN372T were puriﬁed to homogeneity and were inac-
tive as expected. Titration of 45 nM Rv1625cN372T with
Rv1625cD300S reconstituted 16% (0.4 lmol cAMP
mg1 min1) of wild-type activity (Fig. 1(c)) and demonstrated
that the proteins were properly folded, interacting and active.
However, addition of 100 lM forskolin did not activate at all
at 75 lM substrate ATP, whereas it strongly activated an
appropriate mammalian C1/C2 couple run as a positive con-
trol under identical conditions. 75 lM MnATP was used be-
cause mammalian ACs are more sensitive to forskolin at low
MnATP [14]. Mn2þ was also used as a metal-cofactor because
Mg2þ is ineﬀective with Rv1625c [3,8,9].The results suggest
that the evolution of forskolin-sensitivity of mammalian ACs
probably has been accompanied by structural rearrangements
going beyond diﬀerences in those amino acids which line the
non-catalytic pocket and which are in direct contact with
forskolin.
3.2. Chimeras of Rv1625c and mammalian ACs
Next, we tested whether the C2 equivalent Rv1625cD300A
can complement C1 domains from mammalian ACs types I, V
and VII. The recombinant puriﬁed proteins were preincubated
and AC activity was assayed. In no instance did we observe a
functional reconstitution as compared to standard control in-
cubations (see above). We also tested whether mixtures of
Rv1625cD300S and the C1 domains of mammalian type I and
V ACs would yield an active heterodimer. Again, no reconsti-
tution occurred irrespective of the presence or absence of for-
skolin. Next, we used Rv1625cN372A and forskolin-adapted
Rv1625cN372T as C1 equivalent AC domains and the C2 do-
mains of the mammalian ACs types II and IX. As above, robust
reconstitution of AC activity with these formally complemen-
tary bacterial/mammalian AC domains was not detectable. The
absence of AC activity in the mycobacterial-mammalian chi-
meras prohibits a meaningful discussion beyond the conclusion
that the considerable extent of conservation in primary se-
quence, canonical catalytic amino acids and computed protein
structure of Rv1625c and its mammalian AC congeners [1,3,15]
stops short of a structural compatibility. The interacting do-
main surfaces and/or the ATP-binding pockets obviously di-
verged beyond the minimal requirements for a functionally
successful interaction.
3.3. An active chimera of Rv1625c and a Paramecium GC
Earlier we reported that mammalian C2-CHDs from AC
types II and IX can functionally interact with the C2-CHD of a
GC from the ciliate Paramecium which is the equivalent of a
mammalian C1-CHD, whereas reverse chimeras (mammalian
C1/Paramecium C1) are inactive [7,16]. The C2 GC/C2 AC
heterodimer operates as a speciﬁc AC because the substrate-
specifying residues reside in the mammalian C2 domains [7,16].
Does the Paramecium GC C2-CHD complement a function-
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Fig. 3. Titration of 155 nM Paramecium GC C2 domain with
Rv1625cD300A (squares). Circles: Rv1625cD300A alone. Assays were
done with 2 mM Mn2þ and 75 lM ATP. Inset: Reciprocal plot dem-
onstrating the biphasic nature of the titration curve.
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each individual CHD was inactive. However, in the mixture
of both domains a robust AC activity of 6.8 nmol
cAMPmg1 min1 was detected using Mn2þ as a metal-
cofactor. Mg2þ ions did not support activity. As a negative
control, we mixed the inactive Rv1625cN372A mutant (a C1
equivalent) with the Paramecium GC C2 domain, also a C1
equivalent. As expected no AC activity was detectable al-
though Rv1625cN372A was otherwise capable to restore ac-
tivity with the Rv1625cD300A mutant proving its structural
and functional integrity.
As expected, the chimeric heterodimer did not use GTP as a
substrate, because Rv1625cD300A carries the substrate speci-
fying residues (K296 and D365, [3]) and thus enforces ATP
substrate speciﬁcity. A kinetic analysis (45 nM Paramecium
GC C2+9 lM Rv1625cD300A) yielded a KM of 75 lM ATP
and a Vmax of 135 nmol cAMPmg
1 min1 based on the
amount of the Paramecium GC C2 (Fig. 2). The Hill coeﬃcient
was 1.0, in line with the presence of a single catalytic centre.
The Rv1625cD300A/Paramecium GC C2 chimera was in-
sensitive to 100 lM forskolin and was only slightly aﬀected by
1 mM of the P-site inhibitors 20d–30AMP and 20d–30GMP
(20% inhibition for each compound, data not shown).
To determine the aﬃnity of the mycobacterial and ciliate
dimerization epitopes, we titrated 155 nM Paramecium GC C2
(C1 equivalent) with up to 63 lM Rv1625cD300A as a C2
equivalent (Fig. 3). AC activity increased with the concentra-
tion of Rv1625cD300A over three orders of magnitude giving
an almost linear graph on a semi-logarithmic plot (Fig. 3). A
reciprocal plot characterized this behaviour as being biphasic
(Fig. 3, inset). The ﬁrst phase (up to 5 lM Rv1625cD300A),
which obviously corresponded to the formation of heterodi-
mers, had a dissociation constant (KD) of 1.1 lM. The second
phase (KD ¼ 5 lM) may represent the formation of higher
order oligomers, e.g., Paramecium GC C2/(Rv1625cD300A)3,
because oligomerization of the Rv1625c catalytic domains was
previously shown at higher protein concentrations [3]. The
successful titration experiments demonstrated again that the
lack of reconstitution of Rv1625c mutants and mammalian
AC domains could not be ascribed to a reduced ability of the
proteins used here to dimerize, although such defects have
been reported for other Rv1625c mutant proteins [9]. Actually,
the successful heterodimerization showed that a suﬃcient
fraction of monomers was present in the dynamic monomer–0.04
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Fig. 2. Kinetic analysis by a Lineweaver–Burk plot of the Paramecium
GC/Rv1625c chimera. 45 nM Paramecium GC C2 was mixed with 9
lM Rv1625cD300A and assayed with 2 mM Mn2þ and 20–425 lM
ATP.dimer equilibrium because otherwise active heterodimers
would not have formed on a reasonable timescale. The suc-
cessful reconstitution with the Paramecium GC C2 domain
substantiated that heterodimers can successfully form between
Rv1625c mutants and distantly related cyclases from other
organisms, although homodimerization of Rv1625cD300A
probably was a concurrent competing process. Because the
Paramecium GC C1 domain cannot be puriﬁed and is unstable
[7], the theoretically inverse complementary combination of
GC C1 and Rv1625cN372N was not investigated.
The ability of the CHDs from the mycobacterial AC and the
ciliate GC to form an active chimeric catalytic centre highlights
the structural and functional complementarity between a
bacterial and protozoan catalytic domain. From an evolu-
tionary perspective, the protozoan GC is thought to stand
between the mycobacterial and the mammalian AC species. It
can successfully interact with corresponding domains on both
sides of an envisaged class III AC development. This eﬀectively
indicates that primary structure, i.e., sequence conservation
and functional conservation, was retained over more than 3
billion years. Nevertheless, accompanying changes in amino
acid composition altered the ﬁne structure of the dimer sur-
faces suﬃciently to hamper domains interactions. The 3D
structure of the mammalian heterodimer has been resolved at
2.3 A [2] and a structure of the Rv1625c is forthcoming [15]. It
would be most interesting to obtain an X-ray structure of the
protozoan GC catalytic heterodimer to see how structural and
functional parameters evolved independently.References
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